Mesoblast share price dips amid latest class action news

The company is being taken to court by another unhappy shareholder.

| More on:
An unhappy man in a suit sits at his desk with his arms crossed staring at his laptop screen as the PointsBet share price falls

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • The Mesoblast share price is in the red on Thursday, slipping 1.93% to trade at $1.01
  • The dip comes amid news the company has been hit with another class action
  • Mesoblast has vowed to fight the latest allegations and noted it recently settled a similar suit in the US without admitting liability

The Mesoblast Limited (ASX: MSB) share price is slipping lower as the company is hit with another class-action lawsuit.

A shareholder is suing the biotechnology company alleging it misled the market about its remestemcel-L product.

At the time of writing, the Mesoblast share price is $1.01, 1.93% lower than its previous close.

For context, the S&P/ASX All Ordinaries Index (ASX: XAO) is currently also down 1.41%. Meanwhile, the S&P/ASX 200 Health Care Index (ASX: XHJ) is up 0.26%.

Let’s take a closer look at the details.

Mesoblast facing a new class action

The Mesoblast share price is slipping amid news a class action proceeding in the Federal Court of Australia has been served on the company.

Law firm William Roberts Lawyers has brought the action against Mesoblast. The firm is representing a person who bought shares in the company between February 2018 and December 2020.

It alleges the company engaged in unlawful conduct that misled the market about remestemcel-L. 

“Mesoblast will vigorously defend against the proceeding,” the company said in a statement published to the ASX.

It also noted it resolved a similar suit in the United States for $2 million without admitting liability in April. The company’s insurer covered the cost of the settlement.

Mesoblast has reportedly faced multiple class actions in the US on similar allegations.

Previous actions claimed Mesoblast didn’t inform investors about adverse aspects of particular remestemcel-L trials, the Australian Financial Review reported in 2020.

That reportedly prompted the FDA to demand a further controlled study of the drug before it could be given the green light to treat acute graft versus host disease in children.

And it might not be the last time the market hears news of a class action against the company.

Australian law firm Phi Finney McDonald has also been looking into a class action against Mesoblast over the past few months.

Mesoblast share price snapshot

This year has been rough on the Mesoblast share price.

The stock has tumbled nearly 28% year to date. It’s also nearly 45% lower than it was this time last year.

Motley Fool contributor Brooke Cooper has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A scientist in a white coat and glasses puts her arms in the air in a sign of strength and success.
Healthcare Shares

Why this broker is tipping ‘strength in the CSL share price’

A leading broker is feeling positive about the CSL share price...

Read more »

An ASX shares broker analysing a chart tracking the A2 Milk share price
Healthcare Shares

Why Goldman Sachs sees 13% upside for the ResMed share price

Here's why ResMed shares could be in the buy zone...

Read more »

private health insurance diagram.
Healthcare Shares

Goldman names 2 ASX healthcare shares to buy

Here are two healthcare shares that are rated highly...

Read more »

Two happy scientists analysing test results.
Healthcare Shares

Why did the CSL share price beat the ASX 200 on Wednesday?

Why did CSL shares outperform the benchmark ASX 200 index today?

Read more »

Boy in business suit smiles with arms crossed and rockets attached to his back representing the rocketing BrainChip share price
Healthcare Shares

Why did the Race Oncology share price rocket 10% today?

Investors view Race Oncology's latest release in a positive light.

Read more »

A health professional wearing a stethoscope and scrubs shrugs with uncertainty.
Healthcare Shares

How have Polynovo shares been performing since leaving the ASX 200?

The medical device company's shares can't seem to catch a break this week.

Read more »

Scientists in a laboratory look at a computer screen with anticipation on their faces representing positive results released by ASX biotech Recce Pharmaceuticals which have boosted its share price today
Healthcare Shares

‘The largest unmet medical need in human health’: Why this ASX biotech share is surging 28% today

Recce shares are flying high in Tuesday trade.

Read more »

a woman leans forward with her hand behind her ear, as if trying to hear information.
Healthcare Shares

Down 20% in a year, is the Cochlear share price a bargain buy?

Investors need to hear this: Some brokers think Cochlear is an opportunity.

Read more »